<!DOCTYPE html>
<html class="theme-sleek astro-STCLZLJ5" lang="en">
  <head>
    <!-- Global Metadata -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="theme-color" media="(prefers-color-scheme: light)" content="#ffffff">
<meta name="theme-color" media="(prefers-color-scheme: dark)" content="#18181b">
<!-- 
  This is an example. 
  Use https://realfavicongenerator.net to generate the icons and manifest. 
-->
<link href="/favicon.ico" rel="shortcut icon">

    <!-- Primary Meta Tags --><title>Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.</title>
<meta name="title" content="Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.">
<meta name="description" content="Medical Cannabis Awareness New Zealand">


<!-- Open Graph / Facebook -->
<meta property="og:title" content="Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.">
<meta property="og:description" content="Medical Cannabis Awareness New Zealand">
<meta property="og:type" content="article">
<meta property="og:url" content="https://mcanz.org.nz/blog/sativex-in-neuropathic-pain-ms">

<meta property="article:published_time" content="2016-02-06T00:00:00.000Z">





<!-- Twitter -->
<meta property="twitter:title" content="Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.">
<meta property="twitter:description" content="Medical Cannabis Awareness New Zealand">


<meta property="twitter:card" content="summary_large_image">


<!-- {twitter.url && <meta property="twitter:url" content={twitter.url} />} -->

  <link rel="stylesheet" href="/assets/_slug_.2607fc28.css" />
<link rel="stylesheet" href="/assets/_slug_.f022e152.css" /></head>

  <body class="text-text-body bg-bg-body max-w-3xl mx-auto px-4 sm:px-8 astro-STCLZLJ5">
    <header class="astro-FAM4J5CX">
  <a class="skip-to-main astro-FAM4J5CX" href="#main"> Skip to content</a>
  <nav class="astro-FAM4J5CX">
    <section class="astro-FAM4J5CX">
      <ul class="astro-FAM4J5CX">
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/" class="astro-FAM4J5CX header-link unset animated gradient-colors astro-C675TBRQ">Home</a>
</li>
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/blog" class="astro-FAM4J5CX active header-link unset animated gradient-colors astro-C675TBRQ">Blog</a>
</li>
      </ul>
    </section>
  </nav>
</header>

    <main id="main" class="astro-STCLZLJ5">
      <section class="blog-post astro-STCLZLJ5">
        <h1 class="title astro-STCLZLJ5">Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.</h1>
        <time class="publish-date astro-STCLZLJ5">Feb 6, 2016</time>
        <article><p>Authors: <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Russo%20M%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Russo M</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Naro%20A%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Naro A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Leo%20A%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Leo A</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Sessa%20E%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Sessa E</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=D%27Aleo%20G%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">D'Aleo G</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Bramanti%20P%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Bramanti P</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Calabr%C3%B2%20RS%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26764336">Calabrò RS</a>.</p><h3>Abstract</h3><p>OBJECTIVE : The aim of our study was to better investigate the role of Sativex® in improving pain in multiple sclerosis (MS) patients by means of either clinical or neurophysiological assessment.</p><h4>SETTING:</h4><p>Pain is a common symptom of MS, affecting up to 70% of patients. Pain treatment is often unsatisfactory, although emerging drugs (including cannabinoids) are giving encouraging results. Clinical pain assessment in MS is very difficult, and more objective tools are necessary to better quantify this symptom and its potential response to the treatments.</p><h4>SUBJECTS AND METHODS:</h4><p>We enrolled 20 MS patients (10 with and 10 without neuropathic pain), who underwent a specific clinical (such as visual analog scale) and neurophysiological assessment (by means of laser-evoked potentials and transcranial magnetic stimulation), before and after 4 weeks of Sativex administration.</p><h4>RESULTS:</h4><p>One month of drug administration in MS patients with neuropathic pain successfully reduced pain rating and improved quality of life. Interestingly, such effects were paralleled by an increase of fronto-central γ-band oscillation and of pain-motor integration strength.</p><h4>CONCLUSIONS:</h4><p>Our data suggest that Sativex may be effective in improving MS-related neuropathic pain, maybe through its action on specific cortical pathways.</p><p>Original article available at <a href="http://www.ncbi.nlm.nih.gov/pubmed/26764336">Pubmed.</a></p></article>
      </section>
    </main>
    <footer class="astro-5AYKG27L">
  <div class="astro-5AYKG27L">

  </div>
</footer>


  
</body>


</html>